Literature DB >> 30127548

Acute Lymphoblastic Leukemia in Young Adults Treated with Intensive "Pediatric" Type Protocol.

Prasanth Ganesan1, Tenali Gnana Sagar1, Krishnarathinam Kannan1, Venkatraman Radhakrishnan1, Manikandan Dhanushkodi1, Rajaraman Swaminathan2, Shirley Sundersingh3, Trivadi S Ganesan1.   

Abstract

Young adults with acute lymphoblastic leukemia do better when treated on "pediatric" protocols. Young adults (18-30 years) with Ph-negative ALL treated between 2000 and 2014 were retrospectively analyzed. Two-hundred and thirty-two patients were included [median age 21 years (18-30); 176 (76%) males; median WBC 16,000/cmm]. Protocols used were: BFM 95 (N = 147, 63%), MCP-841 (N = 51, 22%), GMALL (N = 21, 9%), INCTR (N = 9, 4%) and UKALL (N = 4, 2%). Complete remission was achieved in 194/232 (84%). Twenty patients (9%) died due to toxicity which was higher with BFM versus others (18/147 vs. 2/85; p = 0.031). After a median follow-up of 48 months, median RFS and OS were 35.5 months (25-46), and 25 months (18-31) and actuarial RFS and OS (5-years) were 45% (37-53) and 39% (32-46). BFM protocol improved RFS (51 vs. 35%, p = 0.027) but not OS (43 vs. 33%, p = 0.2). The survival outcomes reported are 15-20% lower than those reported from West. Better supportive care and risk-adapted therapy may improve outcomes.

Entities:  

Keywords:  Acute lymphoblastic leukemia; BFM protocol; India; Young adult

Year:  2017        PMID： 30127548      PMCID： PMC6081315          DOI： 10.1007/s12288-017-0892-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  15 in total

Review 1.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

2.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Authors:  Nathalie Dhédin; Anne Huynh; Sébastien Maury; Reza Tabrizi; Kheira Beldjord; Vahid Asnafi; Xavier Thomas; Patrice Chevallier; Stéphanie Nguyen; Valérie Coiteux; Jean-Henri Bourhis; Yosr Hichri; Martine Escoffre-Barbe; Oumedaly Reman; Carlos Graux; Yves Chalandon; Didier Blaise; Urs Schanz; Véronique Lhéritier; Jean-Yves Cahn; Hervé Dombret; Norbert Ifrah
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

3.  Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

Authors:  A W Rijneveld; B van der Holt; S M G J Daenen; B J Biemond; O de Weerdt; P Muus; J Maertens; V Mattijssen; H Demuynck; M C J C Legdeur; P W Wijermans; S Wittebol; F M Spoelstra; A W Dekker; G J Ossenkoppele; R Willemze; J J Cornelissen
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 11.528

4.  Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.

Authors:  Rachael Hough; Clare Rowntree; Nick Goulden; Chris Mitchell; Anthony Moorman; Rachel Wade; Ajay Vora
Journal:  Br J Haematol       Date:  2015-12-18       Impact factor: 6.998

Review 5.  How I treat acute lymphoblastic leukemia in older adolescents and young adults.

Authors:  Emily Curran; Wendy Stock
Journal:  Blood       Date:  2015-03-24       Impact factor: 22.113

6.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

7.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Rachel Wade; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Sue Richards
Journal:  Lancet Oncol       Date:  2013-02-07       Impact factor: 41.316

8.  Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

Authors:  Josep-María Ribera; Albert Oriol; Miguel-Angel Sanz; Mar Tormo; Pascual Fernández-Abellán; Eloy del Potro; Eugenia Abella; Javier Bueno; Ricardo Parody; Pilar Bastida; Carlos Grande; Inmaculada Heras; Concepción Bethencourt; Evarist Feliu; Juan-José Ortega
Journal:  J Clin Oncol       Date:  2008-04-10       Impact factor: 44.544

9.  Acute lymphoblastic leukemia in adolescents and young adults in Finland.

Authors:  Anu Usvasalo; Riikka Räty; Sakari Knuutila; Kim Vettenranta; Arja Harila-Saari; Esa Jantunen; Marjut Kauppila; Pirjo Koistinen; Katriina Parto; Pekka Riikonen; Toivo T Salmi; Raija Silvennoinen; Erkki Elonen; Ulla M Saarinen-Pihkala
Journal:  Haematologica       Date:  2008-06-12       Impact factor: 9.941

10.  Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

Authors:  F Hayakawa; T Sakura; T Yujiri; E Kondo; K Fujimaki; O Sasaki; J Miyatake; H Handa; Y Ueda; Y Aoyama; S Takada; Y Tanaka; N Usui; S Miyawaki; S Suenobu; K Horibe; H Kiyoi; K Ohnishi; Y Miyazaki; S Ohtake; Y Kobayashi; K Matsuo; T Naoe
Journal:  Blood Cancer J       Date:  2014-10-17       Impact factor: 11.037
View more
  2 in total

1.  Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia.

Authors:  Pavan Reddy; Ramesh Shankar; Teena Koshy; Venkatraman Radhakrishnan; Prasanth Ganesan; P K Jayachandran; Manikandan Dhanushkodi; Nikita Mehra; S Krupashankar; P Manasa; R P Nagare; R Swaminathan; Krishnarathinam Kannan; T G Sagar; T S Ganesan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-04-17       Impact factor: 0.900

2.  Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).

Authors:  Prasanth Ganesan; Hasmukh Jain; Bhausaheb Bagal; Papagudi G Subramanian; Biju George; Anu Korula; Nikita Mehra; Jayachandran P Kalaiyarasi; Dinesh Bhurani; Narendra Agrawal; Rayaz Ahmed; Smita Kayal; Jina Bhattacharyya; Uday Yanamandra; Suman Kumar; Chepsy C Philip; M Joseph John; Ambily Nadaraj; Omprakash Karunamurthy; Jeyaseelan Lakshmanan; Vikram Mathews; Manju Sengar
Journal:  Br J Haematol       Date:  2021-03-03       Impact factor: 6.998
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.